X

Trial Profile

Evaluation of biologic treatment patterns in patients with Crohn's Disease

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary) ; Vedolizumab (Primary)
Indications Crohn's disease
Focus Adverse reactions; Therapeutic Use

Most Recent Events

27 Oct 2021 Results of two-year pooled analysis (1,943 bio-naive and 2,030 bio-experienced) assessing biologic treatment patterns among crohns disease patients who initiated adalimumab, certolizumab pegol, infliximab, ustekinumab, and vedolizumab, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.
19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020
26 Dec 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com